Pneumococcal Vaccine Allergy: CRM197 Carrier, PPSV23, and Product Selection

It depends on exactly what the reaction was. If you had confirmed anaphylaxis to a DTaP, DT, or Tdap dose, CRM197-conjugated pneumococcal vaccines — Prevnar 13, Vaxneuvance, and Prevnar 20 — are contraindicated because they use a non-toxic mutant of diphtheria toxin as the carrier protein. In that situation, Pneumovax 23 (PPSV23) is the standard alternative because it contains no carrier protein. If your prior reaction was local, vasovagal, or otherwise not IgE-mediated, an allergist can often delabel the diphtheria claim with skin testing and restore access to conjugate vaccines.

Prevnar refers to the pneumococcal conjugate vaccines Prevnar 13 and Prevnar 20, which attach pneumococcal capsular polysaccharides to a CRM197 carrier protein to produce stronger immune memory. They cover 13 and 20 serotypes respectively and use polysorbate 80 as a stabilizer. Pneumovax 23 (PPSV23) is a plain polysaccharide vaccine covering 23 serotypes with no carrier protein and a phenol preservative. Conjugate vaccines produce stronger immunity, especially in young children and older adults; Pneumovax covers more serotypes but with shorter-lived immunity. The ACIP 2024 adult recommendation permits a single dose of Prevnar 20, or a sequential Vaxneuvance-then-Pneumovax schedule.

Local soreness, redness, and swelling after pneumococcal vaccination are common and expected, particularly after PPSV23 which is more reactogenic than the conjugate products. This reflects a normal immune response, not an allergy. Symptoms peak within 24 to 72 hours and typically resolve within a few days with rest, cool compresses, and over-the-counter analgesics like acetaminophen or ibuprofen. Massive arm swelling that appears 4 to 12 hours after a repeat booster, with bruising and significant pain, may represent an Arthus-type Type III reaction in a hyperimmunized patient — this is not an allergy but does prompt deferral of further pneumococcal doses for 5 to 10 years.

No. None of the currently licensed pneumococcal vaccines — Prevnar 13, Vaxneuvance, Prevnar 20, or Pneumovax 23 — contain egg protein, gelatin, yeast, or natural rubber latex. The relevant excipients are the CRM197 carrier protein (in all three conjugate products), polysorbate 80 (in Prevnar 13 and Prevnar 20), polysorbate 20 (in Vaxneuvance), and a phenol preservative (in Pneumovax 23). This makes pneumococcal vaccines a relatively clean option for patients with food or gelatin allergies, though polysorbate 80 and diphtheria toxoid cross-reactivity remain distinct concerns.

CRM197 is a non-toxic mutant form of diphtheria toxin produced by a single amino acid substitution that eliminates toxicity while preserving protein structure. It is used as a carrier protein in all currently licensed pneumococcal conjugate vaccines (Prevnar 13, Vaxneuvance, Prevnar 20), the meningococcal vaccine Menveo, and certain Hib products. Because CRM197 is structurally derived from diphtheria toxin, patients with confirmed IgE-mediated anaphylaxis to diphtheria toxoid may have cross-reactive antibodies to CRM197, making all CRM197-conjugated vaccines contraindicated for them. Pneumovax 23 remains available as a polysaccharide-only alternative.

Anaphylaxis to pneumococcal vaccination is extraordinarily rare. The CDC Vaccine Safety Datalink study (McNeil et al., Journal of Allergy and Clinical Immunology 2016) found an overall vaccine anaphylaxis rate of 1.31 per million doses across all vaccines studied, with PPSV23 specifically reported at approximately 0.2 cases per million doses distributed. By comparison, the risk of severe invasive pneumococcal disease in unvaccinated adults over 65 is orders of magnitude higher. For nearly every patient, the risk-benefit calculation strongly favors vaccination with the appropriate product selected to avoid any documented excipient contraindication.

Current ACIP guidance recommends a spacing interval rather than same-visit administration for the PCV15-then-PPSV23 sequence. For most adults, PCV15 (Vaxneuvance) is given first, followed by PPSV23 at least 1 year later (or at least 8 weeks later for immunocompromised patients). For adults who receive PCV20 (Prevnar 20) alone, no follow-up PPSV23 is needed — a single dose is sufficient. Spacing reduces the risk of hyperimmune Arthus-type reactions and simplifies adverse-event attribution. Your clinician will select the appropriate schedule based on age, comorbidities, and prior pneumococcal vaccination history.